In an interview with the Financial Times, Lilly CEO David Ricks called Britain “probably the worst country in Europe” for drug pricing and added that England is “not an attractive environment for investment.” As a result, he said, Lilly was reconsidering its plan for a $378 million biotech incubator project, which was activated last year in an agreement with the British government.
No more global freeloading on medical innovation
→
CEO David Ricks said last quarter's 45% growth in Lilly's revenue for its Mounjaro diabetes treatment, Zepbound obesity injections and other products in the incretin market wasn’t as big as expected.
Drops for Lilly and Big Tech weigh on Wall Street, even as most stocks rise
→
